Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

More to come: humoral immune responses in MS.
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Daclizumab Therapy for Multiple Sclerosis.
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Phase 3 Study of RPC1063 in Relapsing MS
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Pharmacokinetics of CAMPATH-1H in BMT patients.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP

Pages